Australia markets close in 48 minutes

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.21+0.20 (+1.71%)
At close: 04:00PM EST
12.21 0.00 (0.00%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close12.01
Bid12.12 x 800
Ask12.25 x 4000
Day's range11.68 - 12.52
52-week range2.86 - 35.20
Avg. volume1,239,796
Market cap830.131M
Beta (5Y monthly)0.06
PE ratio (TTM)N/A
EPS (TTM)-1.07
Earnings date03 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.67
  • GlobeNewswire

    The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

    Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstone’s COVID-19 vaccines (CORAL program) T cell immunity against conserved non-Spike epitopes may offer clinical benefit Gritstone-sponsored, CEPI-funded Phase 1 study of Spike (Beta variant) plus novel TCE constructs expected to initiate in South Africa by year end Initial Phase 1 data from Gritstone-sponsored UK study expected early in the first quarter o

  • GlobeNewswire

    Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted fourteen employees nonqualified stock options to purchase an aggregate of 109,000 shares of its common stock with an exercise price of $10.87, which is equal to the closing price of Gritstone’s common stock on November 16, 2

  • GlobeNewswire

    Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2

    Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques Potential for equivalent or more potent immune responses at lower doses with SAM compared to first-generation mRNA vaccines; strong T cell responses observed Initial Phase 1 data from Gritstone-sponsored CORAL study expected early in the first Quarter 2022 EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nas